This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2022 include:
• The industry generated $6.2 billion in deal value across 352 deals in Q3, exhibiting further quarterly declines as punishing macroeconomic conditions continued. YTD deal value, however, remains higher than before the onset of the pandemic.
Please see full publication below for more information.
